复星医药(600196.SH)控股子公司HLX37注射液获临床试验批准

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of HLX37, a dual-specific antibody injection for treating advanced/metastatic solid tumors [1] Group 1: Company Developments - The approved product, HLX37, is a recombinant humanized dual-specific antibody targeting PD-L1 and VEGF, developed independently by the group [1] - The company plans to conduct Phase I clinical trials for HLX37 in China once conditions are met [1] Group 2: Product Details - Preclinical studies indicate that HLX37 can inhibit tumor growth and demonstrates good safety profiles [1]